Fosamprenavir

Generic Name
Fosamprenavir
Brand Names
Lexiva, Telzir
Drug Type
Small Molecule
Chemical Formula
C25H36N3O9PS
CAS Number
226700-79-4
Unique Ingredient Identifier
WOU1621EEG
Background

Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.

Indication

Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a...

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Phase 4
Completed
Conditions
Chronic HIV Infection
HCV Coinfection
Interventions
Drug: Fosamprenavir
First Posted Date
2010-10-18
Last Posted Date
2014-05-30
Lead Sponsor
Fundacion SEIMC-GESIDA
Target Recruit Count
42
Registration Number
NCT01222611
Locations
🇪🇸

Hospital Clínico San Carlos, Madrid, Spain

🇪🇸

Hospital Gregorio Marañón, Madrid, Spain

🇪🇸

Hospital La Paz, Madrid, Spain

and more 3 locations

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

First Posted Date
2010-09-24
Last Posted Date
2017-01-19
Lead Sponsor
ViiV Healthcare
Target Recruit Count
27
Registration Number
NCT01209065
Locations
🇺🇸

GSK Investigational Site, Buffalo, New York, United States

Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir

First Posted Date
2009-01-06
Last Posted Date
2020-11-12
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
24
Registration Number
NCT00817765
Locations
🇳🇱

Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Raltegravir
Drug: Fosamprenavir
Drug: Ritonavir
First Posted Date
2008-12-04
Last Posted Date
2016-01-29
Lead Sponsor
Garden State Infectious Disease Associates, PA
Target Recruit Count
45
Registration Number
NCT00802074
Locations
🇺🇸

Garden State Infectious Disease Associates, PA, Voorhees, New Jersey, United States

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Phase 2
Completed
Conditions
Healthy
Interventions
Drug: Maraviroc
Drug: Fosamprenavir
Drug: Ritonavir
First Posted Date
2008-10-02
Last Posted Date
2016-01-29
Lead Sponsor
Garden State Infectious Disease Associates, PA
Target Recruit Count
45
Registration Number
NCT00764465
Locations
🇺🇸

Garden State Infectious Disease Associates,PA, Voorhees, New Jersey, United States

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Raltegravir
Drug: Fosamprenavir
Drug: Ritonavir
First Posted Date
2008-02-14
Last Posted Date
2016-01-29
Lead Sponsor
Garden State Infectious Disease Associates, PA
Target Recruit Count
44
Registration Number
NCT00614991

Fosamprenavir Expanded Access

Phase 4
Completed
Conditions
Infection, Human Immunodeficiency Virus
First Posted Date
2005-10-18
Last Posted Date
2016-09-12
Lead Sponsor
ViiV Healthcare
Target Recruit Count
85
Registration Number
NCT00240552
Locations
🇨🇭

GSK Investigational Site, Zurich, Switzerland

Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

Phase 2
Completed
Conditions
HIV Infections
Interventions
Drug: Fosamprenavir
Drug: Saquinavir
First Posted Date
2005-07-22
Last Posted Date
2011-12-22
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
61
Registration Number
NCT00122603
Locations
🇫🇷

Service des Maladies infectieuses et tropicales Hopital Bichat Claude Bernard, Paris, France

Fosamprenavir Versus Other Protease Inhibitors

First Posted Date
2004-10-21
Last Posted Date
2018-04-18
Lead Sponsor
ViiV Healthcare
Target Recruit Count
314
Registration Number
NCT00094523
Locations
🇵🇷

GSK Investigational Site, Ponce, Puerto Rico

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

First Posted Date
2004-06-21
Last Posted Date
2011-05-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
866
Registration Number
NCT00085943
Locations
🇨🇭

GSK Investigational Site, St Gallen, Switzerland

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy